Background: Idarucizumab is a specific antidote for the direct thrombin inhibitor oral
Introduction
Idarucizumab (Praxbind) is a specific antidote for the direct thrombin inhibitor oral anticoagulant dabigatran etexilate (Pradaxa). It is a humanised monoclonal antibody fragment that binds free and protein-bound dabigatran as well as its active metabolites with high affinity. Once bound, dabigatran is unable to inhibit thrombin. 1 Idarucizumab is used as a one-off 5 g dose, given as two consecutive intravenous 2.5 g/50 mL infusions, each administered over 5-10 min. 2 Following Food and Drug Administration approval in October 2015, the drug was granted approval by the Australian Therapeutic Goods Administration in October 2016 for use in patients treated with dabigatran who require rapid reversal of the anticoagulant effects for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding. 3 The reversal effect of idarucizumab can be monitored by measuring the patient's dabigatran level using dilute thrombin time (TT) or ecarin clotting time. 4 Where these assays are not generally available in a timely manner, TT and, to a lesser extent, activated partial thromboplastin time (APTT) are often used as proxy indicators of dabigatran's anticoagulant effect. Prothrombin time (PT) is relatively insensitive to dabigatran and may be normal despite being within therapy levels of dabigatran. 5, 6 Idarucizumab was first introduced to Western Sydney Local Health District (WSLHD) in September 2015 as part of a clinical trial (RE-VERSE AD) and then later Funding: None. Conflict of interest: J. Curnow has received honoraria from, and was a member of advisory boards of Boehringer Ingelheim. The other authors have no potential conflicts to disclose. through the Hospital Formulary. Idarucizumab was dispensed through the hospital blood bank and required haematology approval prior to administration. Although treating clinicians were advised to send baseline TT and APTT, idarucizumab could be given to time-critical patients while the blood results were pending if dabigatran was thought to have been ingested within 24 h. TT and APTT were encouraged to be repeated 30 min and 24 h after idarucizumab administration. In order to monitor the use of idarucizumab, a retrospective chart audit was performed from September 2015 to December 2017.
Methods
Ethical approval for the audit was obtained from the WSLHD Human Research Ethics Committee (5187 QA). Patients who received idarucizumab from September 2015 to December 2017 were identified through the blood bank electronic health record. Clinical details and pathology results were extracted from electronic medical records.
Pathology tests were performed by a network of laboratories within NSW Health Pathology. Coagulation tests (TT and APTT) were performed at local WSLHD hospital laboratories where patients were admitted, using Diagnostica Stago reagents for TT and Actin FS for APTT (Siemens Diagnostics), both performed on STA instrumentation from Diagnostica Stago. Dabigatran level was measured by dilute TT with commercial reagents at the central laboratory located at the ICPMR.
Statistical analysis was performed using the computer package IBM SPSS Statistics (IBM Corporation, Armonk, NY, USA). Mann-Whitney test was used to analyse nonparametric continuous variables, and Fisher's exact test for categorical variables. Where the same patient received more than one dose of idarucizumab, only the first episode was included in the statistical analysis.
Results
Twenty-three patients received idarucizumab during the 28-month audit period. One patient received idarucizumab as part of the RE-VERSE AD study. Patient characteristics are summarised in Table 1 . Twenty patients received a single 5 g dose. One patient received two separate 5 g doses: the first dose was administered immediately prior to urgent pericardiocentesis for pericardial effusion. Failing the procedure, with ongoing severe cardiogenic shock and a detectable dabigatran level of 27 ng/mL, a second dose of idarucizumab was administered 2 days later. Despite eventual normalisation of coagulation parameters 4 days after the second dose, the patient died from cardiogenic shock 9 days after the second dose of idarucizumab. One patient inadvertently received 7.5 g, while another patient was incorrectly charted and administered 10 g.
The majority of patients (74%) received idarucizumab for major bleeding. Idarucizumab was administered as an adjunct to standard care, which included endoscopies, blood product transfusions, tranexamic acid and surgical haemostasis, as required. Bleeding was controlled in 15 of 17 patients (88%). One patient had persistent pericardial effusion as described above. A second patient with upper gastrointestinal (GI) bleeding was deemed not suitable for endoscopies or cardiopulmonary resuscitation in view of his advanced metastatic melanoma. The GI bleeding appeared to resolve by day 3 of his hospital admission; however, he was palliated and died on day 6. All six patients (26%) who received idarucizumab prior to urgent surgery/procedure proceeded to have the surgery without any complications. Six patients (26%) died from the following: cardiogenic shock (2), GI bleeding (1), aspiration (1), respiratory failure (1) and sepsis (1) .
Relatively few patients (17%) received additional prohaemostatic agents (Table 1 ). The patients who received prohaemostatic agents all presented with bleeding that was eventually controlled. Of the four patients who received tranexamic acid, two received platelets, fresh frozen plasma and cryoprecipitate as part of the massive transfusion protocol. Despite the availability of threefactor prothrombin complex concentrate (PCC) and recombinant factor VIIa at our hospitals, none of the 23 patients received plasma derivatives.
Therapeutic anticoagulation was resumed in only 30% of patients during the hospital admission. Anticoagulation had not been restarted in any of the six patients who died. The five patients (22%) who recommenced dabigatran during the hospital admission did so at the same dose as pre-admission. At least four more patients (17%) resumed dabigatran after discharge. There were no recorded thrombotic events in any patient.
As expected for 'real-life' patients, the frequency and type of blood tests performed varied greatly between patients. Three patients (13%) did not have baseline coagulation blood tests prior to receiving idarucizumab. This may have been due to clinical urgency or possibly from a lack of clinical guidance. In the 20 patients who had pre-idarucizumab blood tests, 19 had prolonged TT and APTT, often with very high TT (>100 s in 11 patients), reflecting appropriate patient selection for idarucizumab. One patient had normal baseline APTT without a baseline TT or dabigatran level measured, making it difficult to determine the anticoagulant effect from dabigatran. Only five patients (22%) had a dabigatran level sent at baseline, which ranged between 27 and 418 ng/mL. Although TT and APTT (where TT not available) improved at 1 h post-idarucizumab in all patients in whom these were measured, the tests did not normalise to within the reference range in 6 of 15 patients (40%). By 24 h post-idarucizumab, TT and APTT were above the reference range in these six patients as well as an additional four patients (Fig. 1) . Therefore, of the 20 patients who had TT or APTT (when TT not available) measured at 24 h post-idarucizumab, 10 had prolonged results (50%). Correlation between TT and dabigatran level, where measured, is shown in Figure 2 . Three patients had dabigatran level measured at 24 h post-idarucizumab: one had a level of 253 ng/mL (preidarucizumab level not tested), and two had levels below detection limit. Renal impairment at admission was a predictor for prolonged TT/APTT at 24-h postidarucizumab (P = 0.02) (Fig. 3 ). There was a trend towards weight being associated with prolonged TT/APTT at 24 h (P = 0.05); however, age, gender and pre-admission dabigatran dose were not associated. Of the 10 patients with raised TT/APTT at 24 h, 5 subsequently died during the admission (P = 0.05).
Although dabigatran 'rebound' is an important cause of prolonged coagulation parameters at 24 h post-idarucizumab, some of the patients had other potential causes for their persistent coagulopathy. Two patients were further investigated with TT and APTT mixing studies with 1:1 normal plasma, which showed complete correction in both. In the first patient, the raised TT, APTT as well as PT likely resulted from a combination of vitamin K deficiency, raised C-reactive protein 179 mg/L (normal <3 mg/L) and hypoalbuminaemia with albumin 21 g/L (35-50 g/L). 7, 8 An undetectable dabigatran level 
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Internal Medicine Journal 49 (2019) 59-65confirmed dabigatran reappearance was not the cause of this patient's coagulopathy. In the second patient, dabigatran level was not measured to confirm the absence of drug effect; however, it was the treating team's opinion that the persistently raised APTT and PT were due to acute liver failure associated with cardiogenic shock.
The audit identified practice variation with regard to where idarucizumab was charted (national inpatient medication chart, fluid chart, anaesthetics chart, ICU medication chart), charted dose (2 × 2.5 g, 5 g, 5 mg) and charted rate (2.5 g over 5-10 min, 5 g over 30 min, APP (as per protocol), stat). A further issue identified was the lack of documentation of the time dabigatran was last ingested in the majority of patients, despite this stipulation in the locally approved idarucizumab drug protocol. We are currently in the process of improving drug protocol adherence and standardising idarucizumab prescribing in order to prevent administration errors. Dabigatran level (ng/ml)
Thrombin time (seconds) Figure 2 Correlation between thrombin time and dabigatran level in 10 patients who had dabigatran level measured. Horizontal dotted line indicates upper limit of reference range for thrombin time. In our institution, a thrombin time longer than 100 s is reported as '>100 s'. Vertical dashed line indicates detection limit for dabigatran level. 
Discussion
The availability of idarucizumab at WSLHD has allowed six patients to undergo safely urgent procedures and 15 bleeding patients to achieve haemostasis over the 28-month audit period. Our cohort of real-life patients highlights the significant proportion in whom TT/APTT does not normalise after idarucizumab administration. This is consistent with the finding of the RE-VERSE AD study, where at 24 h post-idarucizumab, over 25% of all patients had a raised APTT, approximately 50% of group A patients (uncontrolled bleeding) had a raised TT and over 25% of group B patients (urgent procedure) had a raised TT. 9 In the RE-VERSE AD study, 23% of patients had reappearance of dabigatran levels above 20 ng/mL by 24 h post-idarucizumab; however, this reappearance was associated with recurrent or continued bleeding in only 10 of 114 (9%) patients.
It is therefore critical for clinicians to monitor coagulation blood tests pre-and post-idarucizumab administration. This is particularly important for patients with renal impairment as we found a significant association between renal function at hospital admission and prolonged TT/APTT at 24 h post-idarucizumab. Although TT/APTT is often used as a surrogate marker of dabigatran anticoagulant effect, we were unable to assess the association between renal impairment and definite dabigatran rebound due to an insufficient number of patients with dabigatran level measurements, despite the test's availability at our central laboratory. Nevertheless, our results support the observation that patients with chronic or acute kidney injury are at an increased risk of experiencing a dabigatran rebound. 10, 11 The dabigatran rebound is thought to occur as a result of redistribution of unbound dabigatran from the extravascular to the intravascular compartment. 9 It is plausible that patients with renal failure and, consequently, higher plasma dabigatran levels have increased extravascular concentrations of dabigatran that is redistributed back into the intravascular compartment over time. Like dabigatran, idarucizumab is primarily renally eliminated, yet patients with mild to moderate renal impairment (creatinine clearance >30 mL/min but <60 mL/min) achieved rapid clearance of idarucizumab with <7% of the maximal concentration measurable after 6 h.
12
In patients with prolonged coagulation parameters post-idarucizumab administration, it is important to consider reasons other than dabigatran rebound. This is particularly important if there is a clinical need for correcting the coagulopathy as the treatment may differ. As in the two cases described above, patients who are bleeding or require urgent surgery often have multiple reasons to be coagulopathic, including dilutional coagulopathy from massive transfusion, liver failure and disseminated intravascular coagulation. Although dabigatran level was not frequently measured in our cohort, a drug level could help determine the cause of coagulopathy and guide the need for subsequent doses of idarucizumab. Dabigatran level may not have been requested in the majority of our patients due to unfamiliarity with the test or the lack of knowledge of the test availability. It is also possible that clinicians may not have considered dabigatran level a useful test to guide patient management unless the result was available in a timely manner.
Finally, our audit demonstrated the relatively infrequent use of prohaemostatic agents in our patients, even in those with severe or uncontrolled haemorrhage. This may have been due to a lack of clinical guidance, concerns over potentiating thrombosis risk or clinicians feeling reassured after seeing improvement in coagulation parameters post-idarucizumab administration. The RE-VERSE AD study reported similarly low rates of prohaemostatic treatments, with only 8.5% of patients receiving tranexamic acid, 5.6% plasma derivatives (3-and 4-factor PCC, recombinant factor VIIa and activated PCC), 2.2% cryoprecipitate and 16.3% fresh frozen plasma. 9 The administration of blood component therapy, such as 4-factor PCC or activated PCC, in addition to idarucizumab has been advocated by some authors as a bridge between neutralisation of intravascular dabigatran activity and establishment of clinical haemostasis, which took a median of 2.5 h to achieve in the RE-VERSE AD study. 9, 13 It is therefore important for clinicians to consider using prohaemostatic agents when clinically indicated, rather than relying on idarucizumab alone.
Conclusion
In this largest case series to date of real-life idarucizumab use, the antidote proved to be an important adjunct in the management of bleeding patients taking dabigatran and allowed patients on dabigatran to undergo urgent procedures without any complications. A significant proportion of patients had prolonged TT/APTT postidarucizumab administration, highlighting the importance of monitoring coagulation parameters in all patients 24 h post-idarucizumab administration. Dabigatran level was under-utilised in our cohort; however, this is likely to change with increasing awareness, availability and improved turnaround times of the assay.
Our retrospective audit identified an association between renal impairment and prolonged TT/APTT postidarucizumab. It remains to be seen if this coagulopathy predicts mortality. If future studies confirm the reduced efficacy of idarucizumab in patients with renal failure, clinicians will need to exercise greater caution in prescribing dabigatran to patients who already have, or have the potential to develop, renal impairment.
